Colon Cancer Screening: Tests and Recommendations

Current Guidance From the CDC and US Preventive Services Task Force

Table of Contents
View All
Table of Contents

Colon cancer is the third most common cancer and the second most common cause of cancer-related deaths in the United States. In 2020, an estimated 147,950 Americans were newly diagnosed with the disease while 53,200 died as a result of colon cancer-related complications. Most of those affected (87.7%) were 45 and over.

In light of these statistics, the U.S. Preventive Services Task Forces (USPSTF) recently updated its colorectal cancer screening guidelines, expanding its recommendations to include adults aged 45 to 75. Previously, in their 2016 guidance, screening was only recommended for adults aged 50 to 75. (For older adults, screening may be done but the benefits—in terms of increased life expectancy—may be minimal.)

This article looks at several tests approved by the USPSTF for colon cancer screening, and how they are used. They include direct visualization tests like colonoscopy, as well as less-invasive stool-sample tests for people with lower risk. The screening frequency depends on the test, or combination of tests, that are used.

Pros and Cons of Virtual Colonoscopies

Verywell / Danie Drankwalter

Additional Clinical Guidelines Updated

The American College of Gastroenterology (ACG) also updated their colon cancer screening guidelines in 2021. The guidelines, updated for the first time since 2009, are aligned with the USPSTF. They also call for screening of all adults beginning at age 45.

Earlier screening may help people with a family history of the disease or certain inflammatory bowel diseases that increase risk. Speak with your healthcare provider to know when your screening should begin.

Stool Tests

One of the characteristic symptoms of colon cancer is hematochezia (blood in stool). Stool-based screening tests are used to check for evidence of blood in a stool sample, which can often go unseen in early-stage disease. Newer stool tests also check for cancer biomarkers (a substance or process suggestive of cancer).

Hematochezia can occur for many reasons and, as such, any positive test result only suggests that cancer is possible and that further investigation is needed.

The different stool-based tests also have varying degrees of sensitivity and specificity and may be less accurate in the early stages.

Guaiac-Based Fecal Occult Blood Test (gFOBT)

Occult blood is blood you cannot see with the eye. The guaiac-based fecal occult blood test (gFOBT) involves the placement of a small sample of stool on a piece of paper infused with guaiac (an organic compound derived from the resin of the Guaiacum tree).

Hydroxide peroxide is then applied. If blood is present, the paper will turn blue within seconds.

Although convenient, the gFOBT has a sensitivity of only 31% (meaning that it can correctly confirm a positive result in 31% cases) and a specificity of 87% (meaning that it can correctly confirm a negative result in 87% of cases).

In its latest guidelines, the ACG notes the use of gFOBT testing has been largely replaced by other, more accurate tests that do not require dietary modifications or medication restrictions.

Screening Recommendation

If used, gFOBT screening should be performed annually, according to the Centers for Disease Control and Prevention (CDC).

Fecal Immunochemical Test (FIT)

The fecal immunochemical test (FIT) is a stool-based test that uses a specific antibody to check stool for hemoglobin (a protein in red blood cells that carries oxygen molecules). The FIT is far more accurate and cost-effective than the gFOBT and is associated with improve screening rates in underserved populations.

Despite these benefits, the FIT has its limitations. Hemoglobin degrades at high temperatures and improper storage of stool samples can increase the risk of false-negative readings. Studies have shown that, for this reason alone, the FIT has a lower sensitivity in the summer months compared to winter months.

Moreover, the FIT tends to be less accurate in the early stages of colon cancer. A 2020 review of studies in the American Journal of Gastroenterology concluded that the FIT has a sensitivity of 73% with stage 1 colon cancer, increasing to between 79% and 83% for stage 2, stage 3, and stage 4 disease.

Screening Recommendation

The FIT is typically offered when colonoscopy is declined. As with gFOBT screening, FIT screening should be performed annually.


The FIT-DNA test (also known as a multi-target stool DNA test) is a newer version of the FIT and, in addition to using antibodies to check for hemoglobin, can also detect 10 molecular biomarkers for colon cancer (including KRAS mutations common to many types of cancer).

The first FIT-DNA test approved by the U.S. Food and Drug Administration (FDA) in 2014 is marketed under the brand name Cologuard.

Studies have shown that Cologuard has higher sensitivity in detecting colon cancer than even colonoscopy and can correctly diagnose the disease in 92% of asymptomatic people at average risk of the disease.

With that said, Cologuard is far from perfect. In people with large advanced polyps—those measuring over 10 millimeters in diameter—the test is able to detect fewer than half (42%). This limits Cologuard's ability to detect precancerous polyps before they become malignant.

Moreover, Cologuard has lower specificity than traditional FITs (87% to 90%), increasing the risk of false-positive results.

Screening Recommendation

FIT-DNA tests should be performed every one to three years as directed by your healthcare provider. To increase the accuracy of the test, an entire bowel movement must be sent to the lab.

Home-Based Stool Tests

Both gFOBT and FIT are available as home self-test kits without a prescription. You can also request a prescription from your healthcare provider to purchase an at-home Cologuard test.

These home-based tests may be an option for those who might otherwise avoid screening but are only appropriate for those who are at low risk of colon cancer. This includes people who do not have:

The home-based tests are readily available for purchase online, although some require you to confirm that you are age 45 or over.

With the gFOBT, test results can be rendered immediately at home. With FIT assays and Cologuard, the stool samples are mailed to the lab and the results are returned electronically or by post, usually within several days. The cost of the home kits may or may not be covered by insurance.

As convenient as the tests are, there are drawbacks to their use. Many of the home-based products are not well-studied or standardized. Moreover, user error is common and can undermine the test results.

Cost Considerations

The presumption that at-home tests are cheaper than in-office tests is undercut by the fact that colon cancer screening is mandated as an Essential Health Benefit (EHB) and, as such, is fully covered under the Affordable Care Act.


Colonoscopy is a minimally invasive endoscopic procedure used to view the entire length of the colon (also known as the large intestine). The procedure involves a flexible fiber-optic scope, called a colonoscope, that is inserted into the rectum to view live images of the colon on a video monitor.

Colonoscopy allows the healthcare provider to obtain tissue samples or remove polyps with specialized attachments fed through the neck of the scope.

Colonoscopy is typically performed under intravenous sedation to induce "twilight sleep." Bowel preparation is required a day before the procedure.

Overall, colonoscopy has a sensitivity of roughly 74%, but, unlike stool-based tests, are far more likely to spot high-grade polyps and remove them before they become cancerous. Where colonoscopy sometimes falls short is in its ability to navigate many of the twists and turns in the large intestine.

Women, for example, tend to have longer colons packed into smaller abdominal cavities. As a result, it is often difficult to reach the cecum at the furthest end of the colon (particularly in young, slender women). It can also be difficult to navigate the sharp bend in the colon, called the hepatic flexure, in tall men or people with obesity.

Even so, colonoscopy remains the gold standard for colon cancer screening, according to the American Society of Gastrointestinal Endoscopy (ASGE).

Screening Recommendation

For people at average risk for colon cancer, a colonoscopy should be repeated every 10 years. For people at increased risk, a colonoscopy may be performed more frequently as directed by your healthcare provider.

Flexible Sigmoidoscopy

Flexible sigmoidoscopy is a mini-version of a colonoscopy used to visualize the portion of the bowel closest to the anus, called the sigmoid colon.

The procedure involves a flexible scope, called a sigmoidoscope, which is inserted into the rectum to view only the lower third of the colon. (There are also rigid sigmoidoscopes, but these are rarely used for screening purposes.)

One of the main differences between sigmoidoscopy and colonoscopy—and the one most often cited by people undergoing the procedure—is that bowel preparation tends to be less complicated with sigmoidoscopy. In addition, anesthesia is often not required.

That is not to suggest that sigmoidoscopy is appropriate for everyone. Men, for instance, are more likely to develop cancer in the rectum or sigmoid colon and may benefit from the procedure. By contrast, women are more likely to get cancer in the upper two-thirds of the colon (mainly the cecum and ascending colon) and may not.

Factors like these translate to a lower overall efficacy when compared to colonoscopy. According to a 2019 study published in the International Journal of Colorectal Diseases, sigmoidoscopy was only about half as accurate in detecting cancer with a sensitivity of around 35%.

Screening Recommendation

Due to its reduced sensitivity, the CDC recommends flexible sigmoidoscopy every five years. Alternately, it can be performed every 10 years in tandem with an annual FIT.

Virtual Colonoscopy

Virtual colonoscopy (VC), also known as CT colonography, is a non-invasive imaging study used to visualize the colon. It involves computed tomography (CT), an imaging technique in which multiple X-rays are composited to create three-dimensional "slices" of internal structures.

VC doesn't involve the extensive bowel prep of endoscopic procedures (generally a laxative a day before the procedure and a suppository to clear any remaining residue) and doesn't require sedation or anesthesia of any sort.

VC has yet to play a major role in colon cancer screening, but advances in technology and increasing acceptance among healthcare providers and the public may one day change that. With that said, the benefits of VC are counterbalanced by a number of risks and limitations.

According to 2018 guidance from the American College of Radiologists (ACR), the overall sensitivity and specificity of VC screening are high (90% and 86%, respectively), but the sensitivity drops to 78% when polyps are 6 millimeters or less. Real-world studies suggest that the sensitivity may be closer to 44% when polyps are small.

VC can also miss smaller sessile (flat) polyps. Although these polyps are at no greater or lesser risk of turning cancerous, the fact that they are missed allows them to go unnoticed until such time as they become malignant.

A 2016 study in the journal Radiology reported that more than half of malignant polyps detected in follow-up VC screenings were sessile polyps that had gone unnoticed during the initial VC screening.

  • Overall higher sensitivity and sensivity than colonoscopy

  • Can screen the entire colon in nearly all people

  • No sedation or sedation risks

  • Minimal bowel prepation

  • Lesser risk of injury, including bowel perforation

  • Takes less time than a colonoscopy

  • Costs less than traditional colonoscopy

  • Sensitivity drops with flat polyps or polyps smaller than 10 mm

  • Tends to be less sensitive in people at average risk

  • Retained fluid and stool can trigger false positive results

  • If polyps are detected, a colonoscopy is needed

  • Real-world efficacy often differs from studies in academic centers

  • Not covered by Medicare and most private insurers

At present, VC may be considered for people who decline colonoscopy. For its part, the USPSTF acknowledges its use but has yet to formally endorse VC for colon cancer screening.

Screening Recommendation

If virtual colonoscopy is pursued, the CDC recommends screening every five years.

A Word From Verywell

When it comes to colon cancer screening, there is not one option that is inherently "right." There are pros and cons to each, as well as personal and financial considerations that need to be taken into account (including the resources available for testing and follow-up).

Speak to your healthcare provider to discuss which options are most appropriate for you based on your level of risk. People who have IBD, a personal or family history of colon cancer, or a prior history of abdominal or pelvic radiation may be well served to consider colonoscopy—the procedure of which is rarely as problematic as people think.

20 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. National Cancer Institute/Surveillance, Epidemiology, and End Result Program. Cancer stat facts: Colorectal cancer.

  2. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238.

  3. U.S. Preventive Services Task Force. Colorectal cancer: Screening. June 15, 2016.

  4. Shaukat A, Kahi CJ, Burke CA. et al. ACG clinical guidelines: Colorectal cancer screening 2021. Am J Gastroenterol. 2021 Mar 1;116(3):458-479. doi: 10.14309/ajg.0000000000001122.

  5. Ramdzan AR, Rahim MAA, Zaki AM, Zaidun Z, Nawi AM. Diagnostic accuracy of FOBT and colorectal cancer genetic testing: A systematic review & meta-analysis. Ann Glob Health. 2019;85(1):70. doi:10.5334/aogh.2466

  6. Centers for Disease Control and Prevention. Colorectal cancer screening tests.

  7. Doubeni CA, Jensen CD, Fedewa SA, et al. Fecal immunochemical test (FIT) for colon cancer screening: Variable performance with ambient temperatureJ Am Board Fam Med. 2016;29(6):672-81. doi:10.3122/jabfm.2016.06.160060

  8. Niedermaier T, Balavarca Y, Brenner H. Stage-specific sensitivity of fecal immunochemical tests for detecting colorectal cancer: Systematic review and meta-analysis. Am J Gastroenterol. 2020;115(1):56-69. doi:10.14309/ajg.0000000000000465

  9. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297 doi:10.1056/nejmoa1311194

  10. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED). Device generic name: stool DNA-based colorectal cancer screening test. Device trade name: Cologuard.

  11. Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available optionsWorld J Gastroenterol. 2017;23(28):5086-96. doi:10.3748/wjg.v23.i28.5086

  12. American Cancer Society. American Cancer Society guideline for colorectal cancer screening.

  13. Richman I, Asch SM, Bhattacharya J, Owens DK. Colorectal cancer screening in the era of the Affordable Care ActJ Gen Intern Med. 2016;31(3):315-20. doi:10.1007/s11606-015-3504-2

  14. Waye JD. Difficult colonoscopyGastroenterol Hepatol (N Y). 2013;9(10):676-8.

  15. American Society for Gastrointestinal Endoscopy. Colorectal cancer screening.

  16. White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UKBMC Cancer. 2018;18(1):906. doi:10.1186/s12885-018-4786-7

  17. Ko CW, Doria-Rose VP, Barrett MJ, Kamineni A, Enewold L, Weiss NS. Screening flexible sigmoidoscopy versus colonoscopy for reduction of colorectal cancer mortalityInt J Colorectal Dis. 2019;34(7):1273-81. doi:10.1007/s00384-019-03300-7

  18. Moreno C, Kim DH, Bartel TB, et al. ACR Appropriateness Criteria® colorectal cancer screening. J Am Coll Radiol. 2018;15(5):S56-S68. doi:10.1016/j.jacr.2018.03.014

  19. Weinberg DS, Pickhardt PJ, Bruining DH, et al. Computed tomography colonography vs colonoscopy for colorectal cancer surveillance after surgeryGastroenterology. 2018;154(4):927-34.e4. doi:10.1053/j.gastro.2017.11.025

  20. Pickhardt PJ, Pooler BD, Mbah I, Weiss JM, Kim DH. Colorectal findings at repeat ct colonography screening after initial ct colonography screening negative for polyps larger than 5 mmRadiology. 2017;282(1):139-48. doi:10.1148/radiol.2016160582

By James Myhre & Dennis Sifris, MD
Dennis Sifris, MD, is an HIV specialist and Medical Director of LifeSense Disease Management. James Myhre is an American journalist and HIV educator.